Jun 2026 (Q2 FY26) — Aug 5, 2026
Clover Health Q2 FY26 — Strong MA Membership Growth and Profitability
Read the full callClover Health earnings: last reported Wed, 5 Aug 2026, for the quarter ended Jun 2026.
Reported
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 743 | +55.6% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | 3.8 | +6.0 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | 28.0 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
1Y: $2.71 on 17 Oct 2025 → $4.44. High $5.41 (26 Jun 2026), low $1.7 (1 Apr 2026).
Overview
Call summaries
Clover Health Q2 FY26 — Strong MA Membership Growth and Profitability
Read the full callEvery analysed call
Financials
Net profit, year on year: +365% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 331 | 337 | 462 | 478 | 497 | 488 | 749 | 743 |
| Operating profit | -9 | -21 | -1 | -11 | -24 | -49 | 27 | 28 |
| Operating margin | −2.6% | −6.4% | −0.3% | −2.2% | −4.9% | −10.1% | 3.6% | 3.8% |
| Interest | 0 | 0 | — | — | — | — | — | — |
| Net profit | -9 | -22 | -1 | -11 | -24 | -49 | 27 | 28 |
| EPS ($ per share) | — | — | 0 | -0.02 | — | — | 0.05 | 0.05 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Reserves | -0 | -1,029 | -1,616 | -1,946 | -2,160 | -2,203 | -2,288 |
| Total liabilities | 0 | 433 | 411 | 452 | 284 | 240 | 232 |
| Fixed assets | — | 2 | 2 | 6 | 5 | 5 | 6 |
| Total assets | 0 | 267 | 951 | 809 | 571 | 581 | 541 |
| Line item | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Cash from operations | -160 | -118 | -282 | -204 | -145 | 35 | -67 |
| Cash from investing | -182 | 137 | -435 | 95 | 140 | 1 | 4 |
| Cash from financing | 334 | 6 | 925 | -5 | -5 | -17 | -53 |
| Net cash flow | -8 | 25 | 208 | -114 | -10 | 18 | -116 |
| Capital expenditure | -0 | -1 | -1 | -4 | -1 | -2 | -2 |
| Free cash flow | -160 | -119 | -283 | -208 | -145 | 33 | -69 |
92 filings between Oct 29, 2025 and Oct 7, 2026.
Purchases
None
No insider bought shares.
Sales
$8.14M
35 sales by 8 insiders
89% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Toy Andrew | — | $3.70M | Oct 1, 2026 |
| Wai Conrad | — | $2.41M | Sep 15, 2026 |
| Priest Brady Patrick | — | $724.8K | May 13, 2026 |
| Reynoso Jamie L. | — | $454.4K | Oct 7, 2026 |
| Soares Karen | — | $336.6K | Sep 15, 2026 |
| Edwards Carladenise Armbrister | — | $229.7K | May 18, 2026 |
| OLDAKOWSKI JOSEPH FRANK | — | $176.7K | Sep 16, 2026 |
| THORNTON JOSEPH CLAY | — | $99.7K | Aug 17, 2026 |
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 7, 2026 | Reynoso Jamie L. CEO, Medicare Advantage | Sale 10b5-1 plan | 2,006 | $9.3K |
| Oct 5, 2026 | Reynoso Jamie L. CEO, Medicare Advantage | Sale 10b5-1 plan | 8,750 | $38.7K |
| Oct 1, 2026 | Toy Andrew Chief Executive Officer | Sale 10b5-1 plan | 318,806 | $1.34M |
| Sep 30, 2026 | Torricelli Robert G Director | Award | 12,481 | $0 |
| Sep 30, 2026 | Miller Brian James Director | Award | 12,481 | $0 |
| Sep 17, 2026 | Reynoso Jamie L. CEO, Medicare Advantage | Sale 10b5-1 plan | 1,921 | $8.8K |
| Sep 16, 2026 | OLDAKOWSKI JOSEPH FRANK VP OF FINANCE AND CONTROLLER | Sale 10b5-1 plan | 3,170 | $14.7K |
| Sep 15, 2026 | Wai Conrad CEO, Counterpart Health | Sale 10b5-1 plan | 300,000 | $1.42M |
| Sep 15, 2026 | Reynoso Jamie L. CEO, Medicare Advantage | Sale 10b5-1 plan | 9,273 | $44.3K |
| Sep 15, 2026 | Soares Karen Chief Legal Officer | Sale 10b5-1 plan | 6,846 | $32.7K |
| Sep 14, 2026 | OLDAKOWSKI JOSEPH FRANK VP OF FINANCE AND CONTROLLER | Sale | 20,000 | $103.2K |
| Aug 17, 2026 | THORNTON JOSEPH CLAY Interim CFO | Sale 10b5-1 plan | 17,775 | $78.0K |
| Aug 12, 2026 | Soares Karen Chief Legal Officer | Award | 108,695 | $0 |
| Aug 12, 2026 | THORNTON JOSEPH CLAY Interim CFO | Award | 54,347 | $0 |
| Aug 10, 2026 | Toy Andrew Chief Executive Officer | Sale 10b5-1 plan | 87,798 | $408.3K |
| Jul 20, 2026 | Soares Karen Chief Legal Officer | Sale 10b5-1 plan | 51,700 | $233.2K |
| Jul 17, 2026 | Reynoso Jamie L. CEO, Medicare Advantage | Sale 10b5-1 plan | 4,839 | $21.9K |
| Jul 15, 2026 | THORNTON JOSEPH CLAY Interim CFO | Sale 10b5-1 plan | 4,630 | $21.6K |
| Jul 15, 2026 | Toy Andrew Chief Executive Officer | Sale 10b5-1 plan | 62,711 | $292.9K |
| Jul 15, 2026 | Wai Conrad CEO, Counterpart Health | Sale 10b5-1 plan | 24,215 | $113.1K |
| Jul 15, 2026 | Reynoso Jamie L. CEO, Medicare Advantage | Sale 10b5-1 plan | 13,119 | $61.3K |
| Jul 15, 2026 | Soares Karen Chief Legal Officer | Sale 10b5-1 plan | 10,519 | $49.1K |
| Jul 8, 2026 | Reynoso Jamie L. CEO, Medicare Advantage | Sale 10b5-1 plan | 2,384 | $11.2K |
| Jul 6, 2026 | Reynoso Jamie L. CEO, Medicare Advantage | Sale 10b5-1 plan | 6,229 | $32.8K |
| Jul 1, 2026 | Toy Andrew Chief Executive Officer | Sale 10b5-1 plan | 313,476 | $1.67M |
| Jun 17, 2026 | Reynoso Jamie L. CEO, Medicare Advantage | Sale 10b5-1 plan | 2,360 | $11.3K |
| Jun 16, 2026 | OLDAKOWSKI JOSEPH FRANK VP OF FINANCE AND CONTROLLER | Sale 10b5-1 plan | 12,102 | $58.8K |
| Jun 15, 2026 | Soares Karen Chief Legal Officer | Sale 10b5-1 plan | 4,681 | $21.6K |
| Jun 15, 2026 | Reynoso Jamie L. CEO, Medicare Advantage | Sale 10b5-1 plan | 6,350 | $29.3K |
| Jun 11, 2026 | Reynoso Jamie L. CEO, Medicare Advantage | Sale 10b5-1 plan | 7,289 | $35.8K |
| May 28, 2026 | Wai Conrad CEO, Counterpart Health | Sale 10b5-1 plan | 220,426 | $879.5K |
| May 18, 2026 | Edwards Carladenise Armbrister Director | Sale | 67,160 | $229.7K |
| May 16, 2026 | THORNTON JOSEPH CLAY Interim CFO | Tax withheld | 16,942 | $58.8K |
| May 13, 2026 | Priest Brady Patrick CEO of Clover Care Services | Sale | 98,039 | $345.1K |
| May 8, 2026 | Toy Andrew Chief Executive Officer | Tax withheld | 85,704 | $241.7K |
| Apr 18, 2026 | Priest Brady Patrick CEO of Clover Care Services | Tax withheld | 36,113 | $79.1K |
| Apr 15, 2026 | Soares Karen Chief Legal Officer | Tax withheld | 10,161 | $20.7K |
| Apr 15, 2026 | Wai Conrad CEO, Counterpart Health | Tax withheld | 23,463 | $47.9K |
| Apr 15, 2026 | Priest Brady Patrick CEO of Clover Care Services | Tax withheld | 15,471 | $31.6K |
| Apr 15, 2026 | Reynoso Jamie L. CEO, Medicare Advantage | Tax withheld | 12,712 | $25.9K |
| Apr 15, 2026 | Toy Andrew Chief Executive Officer | Tax withheld | 60,765 | $124.0K |
| Apr 15, 2026 | THORNTON JOSEPH CLAY Interim CFO | Tax withheld | 4,158 | $8.5K |
| Apr 3, 2026 | Reynoso Jamie L. CEO, Medicare Advantage | Tax withheld | 6,197 | $10.7K |
| Apr 1, 2026 | Toy Andrew Chief Executive Officer | Award | 956,307 | $0 |
| Apr 1, 2026 | Soares Karen Chief Legal Officer | Award | 382,522 | $0 |
| Apr 1, 2026 | Priest Brady Patrick CEO of Clover Care Services | Award | 191,261 | $0 |
| Apr 1, 2026 | Wai Conrad CEO, Counterpart Health | Award | 267,766 | $0 |
| Apr 1, 2026 | Reynoso Jamie L. CEO, Medicare Advantage | Award | 159,384 | $0 |
| Apr 1, 2026 | Toy Andrew Chief Executive Officer | Tax withheld | 309,558 | $544.8K |
| Mar 18, 2026 | Reynoso Jamie L. CEO, Medicare Advantage | Sale 10b5-1 plan | 5,833 | $11.1K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Free account. Everything above stays public.
Write why you follow CLOVER HEALTH INVESTMENTS, CORP. /DE and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading